【正文】 w of interleukin2 function, production and clinical applications[J]. Cytokine, 2004,28(3):109123. [7] Fehniger T A, Bluman E M, Porter M M, et al. Potential mechanisms of human natural killer cell expansion in vivo during lowdose IL2 therapy[J]. J Clin Invest, 2000,106(1):117124. [8] Ishizuka O, Tanabe T, Nakayama T, et al. The serum concentration of interleukin2 in a hemodialysis patientreport from interleukin adjuvant therapy for local recurrent renal cancer[J]. Gan To Kagaku Ryoho, 2006,33(3):389390. [9] 莊玉輝, 李國利, 張曉剛, 等. rIL2在小鼠體內抗結核菌能力的研究[J]. 上海免疫學雜志, 1992(2):7677.[10] Wang J, Wicker L S, Santamaria P. IL2 and its highaffinity receptor: genetic control of immunoregulation and autoimmunity[J]. Semin Immunol, 2009,21(6):363371.[11] Yamanouchi J, Rainbow D, Serra P, et al. Interleukin2 gene variation impairs regulatory T cell function and causes autoimmunity[J]. Nat Genet, 2007,39(3):329337.[12] Setoguchi R, Hori S, Takahashi T, et al. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)2 and induction of autoimmune disease by IL2 neutralization[J]. J Exp Med, 2005,201(5):723735.[13] Malek T R, Bayer A L. Tolerance, not immunity, crucially depends on IL2[J]. Nat Rev Immunol, 2004,4(9):665674.[14] Malek T R, Yu A, Vincek V, et al. CD4 regulatory T cells prevent lethal autoimmunity in IL2Rbetadeficient mice. Implications for the nonredundant function of IL2[J]. Immunity, 2002,17(2):167178.[15] Malek T R, Yu A, Vincek V, et al. CD4 regulatory T cells prevent lethal autoimmunity in IL2Rbetadeficient mice. Implications for the nonredundant function of IL2[J]. Immunity, 2002,17(2):167178.[16] Turka L A, Walsh P T. IL2 signaling and CD4+ CD25+ Foxp3+ regulatory T cells[J]. Front Biosci, 2008,13:14401446.[17] Bayer A L, Yu A, Malek T R. Function of the IL2R for thymic and peripheral CD4+CD25+ Foxp3+ T regulatory cells[J]. J Immunol, 2007,178(7):40624071.[18] 郝學志, 王金萬, 孫燕, 等. 重組人白細胞介素2治療晚期腫瘤Ⅱ期臨床研究[J]. 中國新藥雜志, 2005(3):338341.[19] 倪劍鋒, 紀劍飛, 呂安國, 等. 抗GD2單鏈抗體IL2融合蛋白基因的構建及表達[J]. 生物醫(yī)學工程學雜志, 2007(1):170175.[20] Gillies S D, Reilly E B, Lo K M, et al. Antibodytargeted interleukin 2 stimulates Tcell killing of autologous tumor cells[J]. Proc Natl Acad Sci U S A, 1992,89(4):14281432.[21] Harvill E T, Morrison S L. An IgG3IL2 fusion protein activates plement, binds Fc gamma RI, generates LAK activity and shows enhanced binding to the high affinity IL2R[J]. Immunotechnology, 1995,1(2):95105.[22] Klimka A, Yu N, Shami E Y. Construction of proteolysis resistant human interleukin2 by fusion to its protective single chain antibody[J]. Cytokine, 2003,22(5):134141.[23] 魏雪濤, 李銀, 鮑恩東. 馬立克氏病病毒gB與IL2融合基因載體的構建及表達[J]. 南京農業(yè)大學學報, 2005(2):9093.